Skip to main navigation

SEARCH

MEDIA

CAREERS

CONTACT

Nektar
  • Our Company
    • Our Story
    • Our Leadership
    • Our Board of Directors
    • Our Partners
    • Locations
    • Contact
  • Our Pipeline
    • Clinical Resources
    • R&D Pipeline
      • Bempegaldesleukin (NKTR-214)
      • Dapirolizumab Pegol (Anti-CD40L)
      • NKTR-358
      • NKTR-262
      • NKTR-255
    • Clinical Trials
    • Expanded Access
    • Investigator Supported Trials
  • Our Medicines
    • U.S. Medicines Marketed by Our Partners
    • EU Medicines Marketed by Our Partners
    • Investigational Medicines
  • Our Science
    • Research Platform
    • Scientific Posters, Presentations and Publications
    • Scientific & Medical Events
  • Investors

    Investor Relations

    • About Us
    • Press Releases
    • Investor Events
    • Stock Information
      • Historic Stock Lookup
    • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
    • Contact IR
    • Email Alerts
  • Media
    • Media Room
    • Video Gallery
    • Image Gallery
  • Careers
    • Overview
    • Life at Nektar
    • Search Jobs
    • Benefits at Nektar
      • Benefits at San Francisco, California
      • Benefits at Huntsville, Alabama
      • Benefits at Hyderabad, India
    • Information for Recruiters

Nektar Therapeutics Investor & Analyst Event

Sep 13, 2023 at 11:00 AM EDT

Listen to Webcast

Supporting Materials

REZPEG in Atopic Dermatitis and Beyond Investor and Analyst Presentation 2.6 MB

Investor Relations

  • About Us
  • Press Releases
  • Investor Events
  • Stock Information
    • Historic Stock Lookup
  • Analyst Coverage
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
  • Contact IR
  • Email Alerts
Nektar

QUICK LINKS

Our Company

Our Pipeline

Our Medicines

Our Science

Investors

Media

Careers

Contact

Privacy

Terms of Use

CONNECT

LOCATIONS

San Francisco, CA

Hyderabad Office

Huntsville, AL

San Francisco Office
Copyright Nektar © 2023